biostudies-literatureEmerson AGNIAID NIH HHSFoundation for the National Institutes of HealthNational Institutes of HealthAmerican Academy of Allergy, Asthma and Immunology Foundation555-559.e1https://www.ebi.ac.uk/biostudies/studies/S-EPMC12609014biostudies-literatureUnknown135(5)<h4>Background</h4>Dupilumab is a monoclonal antibody that inhibits type 2 inflammation through a blockade of interleukin-4 receptor alpha. It is approved for a number of atopic conditions; however, the effect of dupilumab on food allergy has not been fully evaluated.<h4>Objective</h4>To describe the effect of dupilumab use on the clinical course of food allergy in patients receiving dupilumab for comorbid atopic dermatitis.<h4>Methods</h4>This retrospective study reviewed electronic medical records of children with food allergy at a single, tertiary care center receiving dupilumab for the treatment of atopic dermatitis. Food allergy testing, including skin prick test (SPT) and specific IgE (sIgE), and the outcomes of oral food challenges undertaken during routine clinical care were reviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & ImmunologyFood allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis.PMC12609014K08AI185260K08 AI185260L30 AI186122Krantz MSRobison RGEmerson AGfalseFood allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis.<h4>Background</h4>Dupilumab is a monoclonal antibody that inhibits type 2 inflammation through a blockade of interleukin-4 receptor alpha. It is approved for a number of atopic conditions; however, the effect of dupilumab on food allergy has not been fully evaluated.<h4>Objective</h4>To describe the effect of dupilumab use on the clinical course of food allergy in patients receiving dupilumab for comorbid atopic dermatitis.<h4>Methods</h4>This retrospective study reviewed electronic medical records of children with food allergy at a single, tertiary care center receiving dupilumab for the treatment of atopic dermatitis. Food allergy testing, including skin prick test (SPT) and specific IgE (sIgE), and the outcomes of oral food challenges undertaken during routine clinical care were review2025-01-01T00:00:00Z2025 Nov2026-06-05T15:08:38.142Z2026-05-18T03:12:25.257ZS-EPMC126090144073027310.1016/j.anai.2025.07.023